ArticleCureus2025
Efficacy of Low-Dose Intravenous Immunoglobulin Combined With Immunosuppression Modification in the Treatment of BK Polyomavirus Nephropathy: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New and powerful immunosuppression agents presently available for maintenance immunosuppression and for the treatment of acute and chronic rejection in renal transplantation have led to the emergence of opportunistic infections. One such infection is BK virus nephropathy, leading to graft dysfunction and graft loss. Apart from the reduction and manipulation of immunosuppressive medications, various treatment options such as intravenous immunoglobulin (IVIg), cidofovir, leflunomide, and fluoroquinolones have been tried to treat BK virus nephropathy. We report our experience with low-dose IVIg in six renal transplant recipients with BK polyomavirus nephropathy. We suggest that low-dose IVIg can be a promising treatment option to treat and prevent a decline in renal function and subsequent graft loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.